Skip to content

Prognostic value of lymph node ratio beyond extranodal extension in node-positive oral cavity squamous cell carcinoma.

Nov 2026 · Radiotherapy and Oncology · pp. 111863 · 0 citations · 25 references
Medicine

Abstract

Purpose

Extranodal extension (ENE) is a key determinant of adjuvant therapy in node-positive oral cavity squamous cell carcinoma (OCSCC). However, conventional nodal staging may not fully capture the quantitative burden of nodal disease. We evaluated whether lymph node ratio (LNR) provides additional prognostic value beyond ENE in a large randomized trial cohort.

Methods

AND MATERIALS We performed a retrospective subgroup analysis of 661 node-positive patients from the phase III randomized Oral Cavity Adjuvant Therapy (OCAT) trial. LNR was defined as the metastatic-to-dissected lymph node ratio and categorized as low (<0.10) or high (≥0.10). Overall survival (OS), recurrence-free survival (RFS), and locoregional control (LRC) were estimated using Kaplan-Meier and Cox regression, adjusting for ENE, T stage, N stage, PNI, margin status, LVI, and treatment arm.

Results

With a median follow-up of 91 months, 387 deaths occurred. On multivariable analysis, high LNR remained independently associated with inferior OS (HR 1.43, 95% CI 1.15-1.78; p = 0.001), RFS (HR 1.48; p = 0.001), and LRC (HR 1.40; p = 0.018). High LNR/ENE-positive patients had significantly worse survival than the reference group, low LNR/ENE-negative (HR 2.08, 95% CI 1.47-2.95; p < 0.001). Low LNR/ENE-positive patients trended toward inferior survival (HR 1.36; p = 0.051), while high LNR/ENE-negative patients showed no significant difference (HR 1.12; p = 0.65).

Conclusions

LNR is an independent prognostic factor beyond ENE across OS, RFS, and LRC in node-positive OCSCC. High LNR combined with ENE identifies a distinctly high-risk subgroup, whereas high LNR alone did not significantly impact survival in the absence of ENE. Incorporating LNR into postoperative risk stratification may refine identification of patients for risk-adapted adjuvant strategies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.